113 related articles for article (PubMed ID: 26272173)
1. Effect of subcutaneous insulin detemir on glucose flux, lipolysis and electroencephalography in type 1 diabetes.
Herring R; Knight R; Shojaee-Moradie F; Johnsen S; Umpleby AM; Jackson N; Jones R; Dijk DJ; Russell-Jones DL
Diabetes Obes Metab; 2015 Nov; 17(11):1100-3. PubMed ID: 26272173
[TBL] [Abstract][Full Text] [Related]
2. Effect of subcutaneous insulin detemir on glucose flux and lipolysis during hyperglycaemia in people with type 1 diabetes.
Herring RA; Shojaee-Moradie F; Umpleby AM; Jones R; Jackson N; Russell-Jones DL
Diabetes Obes Metab; 2015 May; 17(5):459-67. PubMed ID: 25580665
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes.
Smeeton F; Shojaee Moradie F; Jones RH; Westergaard L; Haahr H; Umpleby AM; Russell-Jones DL
Diabetologia; 2009 Nov; 52(11):2317-23. PubMed ID: 19707744
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.
Plank J; Bodenlenz M; Sinner F; Magnes C; Görzer E; Regittnig W; Endahl LA; Draeger E; Zdravkovic M; Pieber TR
Diabetes Care; 2005 May; 28(5):1107-12. PubMed ID: 15855574
[TBL] [Abstract][Full Text] [Related]
5. Cerebral blood flow and glucose metabolism in appetite-related brain regions in type 1 diabetic patients after treatment with insulin detemir and NPH insulin: a randomized controlled crossover trial.
van Golen LW; IJzerman RG; Huisman MC; Hensbergen JF; Hoogma RP; Drent ML; Lammertsma AA; Diamant M
Diabetes Care; 2013 Dec; 36(12):4050-6. PubMed ID: 24130356
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp.
Hordern SV; Wright JE; Umpleby AM; Shojaee-Moradie F; Amiss J; Russell-Jones DL
Diabetologia; 2005 Mar; 48(3):420-6. PubMed ID: 15729576
[TBL] [Abstract][Full Text] [Related]
7. Short-term effects of NPH insulin, insulin detemir, and insulin glargine on the GH-IGF1-IGFBP axis in patients with type 1 diabetes.
Ma Z; Christiansen JS; Laursen T; Lauritzen T; Frystyk J
Eur J Endocrinol; 2014 Oct; 171(4):471-9. PubMed ID: 25005937
[TBL] [Abstract][Full Text] [Related]
8. Continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) of rapid-acting insulin analogues and detemir in type 1 diabetic (T1D) pregnant women.
Mello G; Biagioni S; Ottanelli S; Nardini C; Tredici Z; Serena C; Marchi L; Mecacci F
J Matern Fetal Neonatal Med; 2015 Feb; 28(3):276-80. PubMed ID: 24724804
[TBL] [Abstract][Full Text] [Related]
9. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
[TBL] [Abstract][Full Text] [Related]
10. Insulin detemir reduces weight gain as a result of reduced food intake in patients with type 1 diabetes.
Zachariah S; Sheldon B; Shojaee-Moradie F; Jackson NC; Backhouse K; Johnsen S; Jones RH; Umpleby AM; Russell-Jones DL
Diabetes Care; 2011 Jul; 34(7):1487-91. PubMed ID: 21593292
[TBL] [Abstract][Full Text] [Related]
11. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR
Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
[TBL] [Abstract][Full Text] [Related]
12. A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes.
Korsatko S; Glettler K; Olsen KJ; Wutte A; Bock G; Koehler G; Mader JK; Semlitsch B; Pieber TR
Diabetes Obes Metab; 2013 Mar; 15(3):241-5. PubMed ID: 23013357
[TBL] [Abstract][Full Text] [Related]
13. Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans.
Sørensen LP; Brock B; Mengel A; Rungby J; Moller N; Nielsen S; Vølund A; Schmitz O
Diabet Med; 2010 Jul; 27(7):830-7. PubMed ID: 20636965
[TBL] [Abstract][Full Text] [Related]
14. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
[TBL] [Abstract][Full Text] [Related]
15. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes.
Kiess W; Raile K; Galler A; Kapellen T
Diabetes Care; 2004 Oct; 27(10):2567-8. PubMed ID: 15451944
[No Abstract] [Full Text] [Related]
16. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
Robertson KJ; Schoenle E; Gucev Z; Mordhorst L; Gall MA; Ludvigsson J
Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321
[TBL] [Abstract][Full Text] [Related]
17. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.
Porcellati F; Rossetti P; Busciantella NR; Marzotti S; Lucidi P; Luzio S; Owens DR; Bolli GB; Fanelli CG
Diabetes Care; 2007 Oct; 30(10):2447-52. PubMed ID: 17623819
[TBL] [Abstract][Full Text] [Related]
18. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
Malek R; Ajili F; Assaad-Khalil SH; Shinde A; Chen JW; Van den Berg E
Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023
[TBL] [Abstract][Full Text] [Related]
19. Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
Hermansen K; Davies M
Diabetes Obes Metab; 2007 May; 9(3):209-17. PubMed ID: 17391147
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection.
Lucidi P; Porcellati F; Marinelli Andreoli A; Carriero I; Candeloro P; Cioli P; Bolli GB; Fanelli CG
Diabetes Care; 2015 Dec; 38(12):2204-10. PubMed ID: 26358287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
